Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock

Edgewise Therapeutics, Inc. , a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price...

Related Keywords

Boston ,Massachusetts ,United States ,Deerfield ,San Francisco ,California ,Wedbush Pacgrow ,Nasdaq ,Deerfield Management Company ,Leerink Partners ,Frazier Life Sciences ,Edgewise Therapeutics Inc ,Wedbush Securities Inc ,Syndicate Department ,Securities Exchange ,Novo Holdings ,Exchange Commission ,Edgewise Therapeutics ,Venrock Healthcare Capital Partners ,Cormorant Asset Management ,Janus Henderson Investors ,Perceptive Advisors ,Surveyor Capital ,Registration Statement ,Securities Act ,Securities Exchange Act ,Markets ,